Medicure Inc. | Cash Flow

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
2,574.30
1,195.60
1,668.40
26,982.60
43,420.90
3,925.60
Depreciation, Depletion & Amortization
537.00
433.10
690.90
2,381.00
7,807.00
299.20
Other Funds
-
-
-
-
21,693.30
6,441.20
Funds from Operations
1,783.40
1,016.90
6,046.20
6,701.20
22,472.90
1,997.40
Changes in Working Capital
792.90
740.40
5,903.40
291.60
44,396.00
2,739.70
Net Operating Cash Flow
990.50
276.50
142.80
6,409.60
21,923.10
742.30
Capital Expenditures
7.40
23.90
226.60
464.20
1,321.80
Sale of Fixed Assets & Businesses
-
-
-
-
89,719.60
Net Investing Cash Flow
7.40
23.90
226.60
42,175.80
54,150.20
Issuance/Reduction of Debt, Net
-
-
694.40
55,436.60
75,120.90
Net Financing Cash Flow
-
6.10
3,119.30
57,319.90
95,780.00
Net Change in Cash
997.70
259.60
3,074.70
21,506.70
19,814.80
Free Cash Flow
993.60
259.80
83.80
5,945.40
20,728.40
Deferred Taxes & Investment Tax Credit
-
-
379.00
301.50
1,513.90
219
Net Assets from Acquisitions
-
-
-
41,711.50
34,247.60
Change in Capital Stock
-
6.10
3,813.70
1,883.30
1,034.30
Exchange Rate Effect
0.10
0.90
39.20
47.10
108.10

About Medicure

View Profile
Address
1250 Waverley Street
Winnipeg Manitoba R3T 6C6
Canada
Employees -
Website http://www.medicure.com
Updated 07/08/2019
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of human therapeutics. It focuses on the marketing and distribution ofits acute care cardiovascular drug, AGGRASTAT. The company was founded by Albert D.